40年狼疮肾炎队列结局评估
结果显示5年死亡率从第一年代24.1%降至第二年代4%后趋于稳定,5年进展至终末期肾病率保持稳定,提示需新治疗与管理策略。
要点
- 狼疮肾炎5年死亡率从1975-1985年的24.1%降至1986-1995年的4%,此后30年稳定。
- 5年进展至终末期肾病率在各年代间保持稳定。
- 患者种族分布变化:白人比例下降,非洲裔比例上升。
核心结论
- 尽管过去20年狼疮肾炎治疗有所变化,但5年死亡率和进展至终末期肾病率已达到平台期。
- 提示需要新的治疗和管理方法以及提高依从性的策略来进一步改善狼疮肾炎患者结局。
研究设计与样本
- 按诊断年代分为四组:1975-1985(D1)、1986-1995(D2)、1996-2005(D3)、2006-2015(D4)。
主要发现
- 白人比例从D1的58.6%降至D4的31.3%(P=0.018),非洲裔比例从17.2%升至39.6%(P=0.040)。
- IV型肾炎比例从D1的51.7%降至D4的27.1%(P=0.035),II型肾炎比例从D2的10%升至D4的18.8%(P=0.01)。
- 抗可提取核抗原抗体阳性率从D1的17.2%升至D4的83.3%(P=0.0001)。
- 5年死亡率从D1的24.1%降至D2的4%,随后30年稳定。
- 5年进展至终末期肾病率在各年代间保持稳定。
关键数值与推荐
- 5年死亡率:D1为24.1%,D2为4%,此后稳定。
- IV型肾炎比例:D1为51.7%,D4为27.1%(P=0.035)。
- II型肾炎比例:D2为10%,D4为18.8%(P=0.01)。
- 抗可提取核抗原抗体阳性率:D1为17.2%,D4为83.3%(P=0.0001)。
临床怎么用
- 临床应关注狼疮肾炎患者5年死亡率和终末期肾病风险已进入平台期,需探索新的治疗与管理策略。
- 应重视提高患者治疗依从性以进一步改善结局。
局限性
- 本研究为单中心回顾性观察性研究。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterize a LN cohort over 40 years, assessing its evolution, analysing two major outcomes: the development of end-stage renal disease and mortality rates in the first 5 years after LN diagnosis. METHODS: An observational retrospective study of patients with LN, followed up from 1975 at University College Hospital. Patients were divided into four groups, depending on the decade of LN diagnosis: 1975-1985 (D1), 1986-1995 (D2), 1996-2005 (D3) and 2006-2015 (D4). Comparison between groups was performed with respect to demographic, clinical, serological and histological characteristics and outcome. RESULTS: Two hundred and nineteen patients with LN were studied. There was a change in ethnic distribution, with a decreasing proportion of Caucasians (58.6% in D1 to 31.3% in D4, P = 0.018) and increase in African-ancestry (17.2% in D1 to 39.6% in D4, P = 0.040). Serological and histological patterns changed throughout time, with a reduction in class IV nephritis (51.7% in D1 to 27.1% in D4, P = 0.035), and increase in class II nephritis (10% in D2 to 18.8% in D4, P = 0.01) and anti-extractable nuclear antigen antibody positivity (17.2% in D1 to 83.3% in D4, P = 0.0001). The 5-year mortality rates decreased from D1 (24.1%) to D2 (4%), stabilizing for the next 30 years. The 5-year progression to end-stage renal disease remained stable over the decades. CONCLUSION: Despite the changes in treatment of LN in the past 20 years, we have reached a plateau in 5-year mortality and progression to end-stage renal disease rates, suggesting that new therapeutic and management approaches, and strategies to enhance adherence, are needed to improve outcomes further in LN patients.
引用
- Gisca E, Duarte L, Farinha F, et al. Assessing outcomes in a lupus nephritis cohort over a 40-year period. Rheumatology (Oxford). 2021. PMID: 33111137. doi:10.1093/rheumatology/keaa491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。